Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, ...

Researchers at the Hong Kong University of Science and Technology (HKUST) have developed the world's first kilowatt-scale elastocaloric cooling ...

Researchers at the Hong Kong University of Science and Technology (HKUST) have developed the world’s first kilowatt-scale ...

Researchers at the Hong Kong University of Science and Technology (HKUST) have developed the world's first kilowatt-scale ...

Strategic deconsolidation of Legend Biotech unlocked significant value, while core businesses experienced rapid growth. PISCATAWAY, N.J., March 12, 2025 /PRNewswire/ ...

CAMBRIDGE, MA, USA I March 11, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase ...

Despite being a renewable energy superpower, China faces potential challenges including overcapacity, slow global demand, and ...